It is possible that alterations in sex hormone-binding globulin (SHBG) binding capacity are due to changes in binding kinetics rather than changes in concentration and, therefore, the immunoreactivity of SHBG may not reflect the binding activity. In this study an immunoradiometric (IRMA) assay was evaluated and the results compared with those of an established binding capacity assay. The correlation between the results of the IRMA (y) and binding assay (x) for 179 specimens was r=0·984, y=0·95x+5·9. Irrespective of the method used. SHBG values in normal non-pregnant women were significantly (P«).(15) higher than those in normal men. hirsute women. women with polycystic ovary syndrome. hyperprolactinaemic women and obese women. and were significantly less than those in pregnant women; SHBG levels in hirsute women rose during treatment with certain anovulants and fell in genetic males during the second decade of life independent of androgen levels or activity. While being technically simpler SIIBG-IRMA provides comparable results to the classical binding assay, indicating that immunoreactivity is an excellent index of binding activity.
Plasma sex hormone-binding globulin (SHBG) is a glycoprotein of molecular mass 90 000-100 000 daltons, consisting of heterogenous monomers and possessing one steroid binding site per dimeric molecule. I Measurement of plasma SHBG is useful in the investigation and management of androgen excess states because an index of the free testosterone concentration may be obtained by expressing plasma total testosterone levels as a function of the plasma SHBG concentration.? Plasma SHBG has usually been estimated by methods based on the capacity of plasma to bind a 3H-steroid under saturating conditions.V 4 In recent years a number of immunoassay methods for plasma SHBG measurement have been described.r" Because of the complex structure of SHBG and since little is known about its synthesis and metabolism," it appears possible that the immunoreactivity of SHBG may not always Correspondence 360 reflect binding activity. This possibility was supported by suggestions that physiological and pathological alterations in plasma SHBG levels are due to changes in binding characteristics of SHBG rather than changes in the concentration of SHBG. IO • II The purpose of this study was to evaluate an immunoradiometric (IRMA) method for SHBG and to compare the results obtained using the immunoassay with those of an established binding capacity method in a variety of physiological and pathological situations and following oestrogen-progestogen therapy.
Materials and methods

SHBG BINDING ASSAY
The binding assay was performed according to Anderson et al. 4 Plasma (25 f.tL) diluted I in 8 with buffer (0·09 M phosphate. 0·9% NaCI. pH 7,4) was mixed with three tritiated dihydrotestosterone (DHT) standards (0·3 mL) of known specific activity. chosen so that satura-ting conditions were obtained with at least two of them.
Duplicate tubes for each of the three standards and triplicate tubes for non-specific binding (including an excess of unlabelIed DHT) were set up for each specimen analysed. The tube contents were then incubated for 30 min at ambient temperature (approximately 200C) folIowed by 60 min at 4°C. The SHBGbound DHT was separated from unbound DHT by adding saturated ammonium sulphate (0·5 mL), at 4°C, while mixing each tube. FolIowing centrifugation at 3000 g and 4°C for IS min the supernatants were decanted into glass scintillation vials. The 3H-radioactivity was counted and the amount of DHT bound was calculated using the known specific activity of the standards and efficiency of the liquid scintillation counter. Results were expressed as nmol/L, assuming that I nmol SHBG binds 1 nmol DHT.
SHBG IMMUNORADIOMETRIC ASSAY (IRMA)
The IRMA method was performed using reagents from Farmos Diagnostica (Oulunsalo, Finland) and folIowing the recommended procedure except for a prolonged incubation period with the solid-phase second antibody. Plasma specimens and calibrators (human pregnancy serum diluted with bovine serum containing 2·5% lactose and 0·1% sodium azide) were diluted I in 100 (1 in 400 for expected values >100 nmoVl) with buffer (0,025 M phosphate, 0·9% NaCl, 0·625% lactose, I% bovine foetal serum and 0·05% sodium azide, pH 7·6). The SHBG content of the human pregnancy serum used in the calibrators was determined by Scatchard analysis using nine different concentrations of tritiated DHT. 12 This serum was then diluted in bovine serum to yield SHBG concentrations of 6·25, 12·5, 25, 50, 100 and 200 nmoVL before dilution. Duplicate aliquots (100 ilL) of the diluted plasma were incubated with a mixture (200 Ill) of SHBG antiserum (rabbit) and 40 000 dpm 12sl_labelIed monoclonal SHBG antiserum (mouse) for 60 min at ambient temperature. A suspension of solidphase second antibody (donkey anti-rabbit IgG, 0·5 ml) was then added and the mixture incubated for 30 min at ambient temperature. FolIowing centrifugation at 3000 g for 15 min the supernatant was decanted and the 12s1 radioactivity was counted. The concentration of SHBG was calculated by interpolation from the calibration curve, which was fitted using a smoothed spline function (lKB Multigamma II gamma counter, LKB WalIac Instruments, Turku, Finland). To examine specificity solutions of human plasma proteins in phosphatebuffered saline (0,025 M phosphate, 0·9% NaCl, pH 7,6) were submitted to the immunoassay without performing the usual 1 in 100 dilution step. The concentrations used were as follows: albumin 50 giL, IgA 2 gil, IgG 20 gil, fibrinogen 1 giL, a-antitrypsin 5 gIL, transferrin 10 gIL, haptoglobin 2 giL, orosomucoid 5 gIL and plasminogen O·33giL. These concentrations were chosen to reflect predilution concentrations in plasma equivalent to at least 20 times physiological values. 13 MATERIALS DHT standards and human plasma proteins were obtained from Sigma Chemical Co (Poole, Dorset, UK) and tritiated DHT was obtained from Amersham International pte (Buckinghamshire, UK).
SUBJECTS
Blood specimens were obtained.from 33 normal women, aged 18-25 years, 29 normal men, aged 18-30 years, eight pregnant women at the end of the first trimester, 32 women with idiopathic hirsutism (hirsutism associated with regular ovulatory menstruation), 18 women with the polycystic ovary syndrome (PCOS), seven women with oligomenorrhoea and obesity, 11 women with hyperprolactinaemia, 29 hirsute women during therapy with anovulants, five men with gynaecomastia and seven men presenting with infertility. In addition, blood specimens were obtained over a period of months or years from two genetic males with complete androgen insensitivity and four males with isolated gonadotrophin deficiency. PCOS patients were alI hirsute and had oligomenorrhoea (less than eight menstrual cycles/year) or amenorrhoea. Pelvic and/or ultrasound examination findings were consistent with PCOS. Ultrasound examination was not generally performed in hirsute patients with regular ovulatory menstrual cycles or in the other groups of patients.
STATISTICAL ANALYSIS
Linear regression analysis was performed using Deming's method as described by Payne. 14 The significance of differences between groups was determined by analysis of variance (performed following logarithmic transformation of the 
SPECIFICITY
All of the human plasma proteins examined were <6·25 nmollL in the SHBG-IRMA at DOSE-RESPONSE CURVE AND ANAI.YTICAI.
SENSITIVITY OF THE IRMA
A dose-response curve was established using dilutions of the calibrators provided by Farmos Diagnostica (Fig. 1 ). The limit of sensitivity (defined as the concentration corresponding to the mean+3 SO of the blank cpm) is 1fmol/tube, which corresponds to 1 nmoVL in a specimen before 1:100 dilution with buffer. At SHBG concentrations above 200 fmolltube, a 'hook-effect' is seen. i.e. counts bound decrease with increasing analyte concentration.
were very similar to those obtained with the binding assay. 
Results
PRECISION (TABLE 1) The between-assay coefficient of variation (CV) for the SHBG immunoassay was derived from values obtained for two serum pools provided by Farmos Diagnostica and three inhouse plasma pools measured in 14 assays. The average CV obtained with the immunoassay for the in-house pools was 5·3%, compared to 7·1% for the binding assay. The within-assay CV for the immunoassay was calculated according to Rodbard!" using results obtained for the three in-house pools each measured twice in each of five to seven assays. Initially, when the assay was performed exactly as recommended by Farmos Diagnostica, there was considerable downward drift in the results from the beginning to the end of the assay. Consequently, the within-assay CV was high (average 8%). On investigation it was found that the SHBG values obtained increased gradually when the incubation period with solid-phase antibody was increased up to 25 min; SHBG values remained constant when this incubation period was increased beyond 25 min. Consequently, an incubation period of 30 min was utilised rather than the recommended 15 min. The average within-assay CV was then 5·5%; the CV for the three individual pools are shown in Table I . Within-assay CV for the binding assay (8·3%) was only determined using a fourth 'in-house' pool which was not measured using the immunoassay. The mean .values obtained for the three in-house pools using the immunoassay data) using the least significant difference method to allow for multiple comparisons. 15 Differences were deemed to be significant at the 5% level and more precise estimations were not sought. concentrations 20-fold higher than occur under physiological conditions. When plasma specimens from a number of subjects (two pregnant subjects, two normal women, one hirsute woman receiving Norinyl, one obese woman and one normal man) were assayed at three or four dilutions, similar results were obtained for each specimen after correcting for the dilution factor (Fig. 2) . This suggests that the SHBG in these specimens is immunologically similar to that in the pregnancy serum calibrators. Heat inactivation (1 h at 600C) of a plasma specimen containing 58 nmollL SHBG, or precipitation of the globulins with 50'Yo saturated ammonium sulphate, resulted in undetectable levels of SHBG when measured with the immunoassay «6·3 nmol/L) and with the binding assay «10 nmoI/L).
COMPARISON OF RESULTS OF SHBG IMMUNOASSAY AND BINDING ASSAY
The plasma SHBG values obtained for blood specimens from 179subjects using the immunoassay correlated very well with values obtained using the binding assay (r=O'984, P<O·OOI). Linear regression analysis of the 179 pairs of values yielded the equation: y=O'95x+5 '9, where y represents SHBG immunoassay results and x represents SHBG binding assay results, expressed as nmollL (Fig. 3 ). In this figure also the means of the various subgroups of subjects are plotted. The points representing the mean values for each subgroup fall very close to the line obtained by linear regression analysis of the 179 individual values; thus no subgroup displayed a significant disparity between the results of the two methods. The mean values in the normal subjects and in the subgroups of patients before treatment are set out in numerical form in Table 2 .
Irrespective of the method used SHBG values in idiopathic hirsutism, polycystic ovary syndrome, hyperprolactinaemic women and obese women were all significantly lower than in normal women, and values in pregnant women were higher than in normal women (P<O·05). SHBG values in normal women were significantly greater than those in normal men. Plasma SHBG values were significantly higher in men presenting with infertility or with gynaecomastia than in normal men using the binding assay (P<O·05), but statistically significant differences were not demonstrated using the immunoassay.
SHBG IMMUNOASSAY VALUES IN GENETIC MALES WITH DISORDERED PUBERTY
Using the immunoassay method we demon- strated that plasma SHBG levels fell with age in two phenotypic females (46 XY siblings) with complete androgen insensitivity ( Fig. 4) . Immunoassay results also demonstrate that SHBG values correlate inversely with age in 14 blood specimens, obtained over periods from 4 months to 4 years, from four males with isolated gonadotropin deficiency (r=-0-854, P<O-OOI).
PLASMA SHBG LEVELS IN HIRSUTE PATIENTS ON ANOVULANT THERAPY
Plasma SHBG was measured using both the immunoassay and binding assay, in hirsute patients treated with four types of anovulants: ethinyloestradiol 50 J.1.glcyproterone acetate 2 mg (Dianev, 11 subjects); mestranol 50 f.&glnorethisterone 1 mg (Norinyl 1, seven subjects); ethinyloestradiol30 f.&glievonorgestrel 150 f.&g (Microgynon 30, six subjects); and ethinyloestradiol 30 f.&glievonorgestrel 250 ug (Ovran 30, five subjects). The plasma SHBG values before and during anovulant therapy obtained using the immunoassay, are shown in Table 3 . Basal SHBG values were similar in the therapy. SHBG values in patients during treatment with Diane were significantly higher than those in patients treated with Ovran 30, Microgynon 30 and Norinyl I (P<0·05). SHBG values during Norinyl I therapy were significantly greater than during Microgynon 30 and Ovran 30 therapy. Values during Microgynon 30 therapy were not significantly higher than during Ovran 30 therapy. Similar results were obtained using the binding assay (not shown).
Discussion
The between-assay precisron of the plasma SHBG immunoassay (5·3%) is at least as good as that of the dihydrotestosterone-binding assay. The sensitivity of 1 fmoVtube, which corresponds to an SHBG concentration of 1 nmoVL before 1:100 dilution with buffer, is more than adequate for clinical use. The lowest SHBG concentration encountered in our laboratory to date is 3·5 nmoVL. The 'hook-effect' of the dose response curve at high analyte concentrations is a feature of many immunoradiometric assays." This problem can be overcome by further diluting specimens with high SHBG concentrations. If specimens with values > 100 nmoVLare diluted 1:400 with buffer prior to assay, the 'hook-effect' will not occur until SHBG concentrations of 800 nmoVL before dilution are reached in plasma. Since SHBG levels of this magnitude are unlikely even in pregnancy, the IRMA will reliably measure SHBG if the recommended dilution protocol is followed (1:100 dilution for specimens with expected values of <100 nmoVL and 1:400 for specimens withexpected valuesof>lOOnmoVL). There was no interference in the SHBG immunoassay by a number of plasma proteins even when present in concentrations equivalent to over 20 times higher than normal. Heat inactivation of plasma at 6O"C resulted in loss of both binding and immunological activity, suggesting that the correct three-dimensional configuration of SHBG is necessary for binding activity and immunoactivity, at least in this immunoradiometric assay. Parellelism was demonstrated by the immunoassay for a wide range of SHBG values, indicating that the SHBG present in these specimens is immunologically similar to that in the calibrators. The observation that parellelism was maintained at plasma dilutions of 1:50 to 1:4 for the specimen with a value of 3·5 nmoVL(from a grossly obese woman) suggests that the sensitivity of the assay is such that it may be applicable to the measurement of low concentrations of SHBG in biological fluids other than plasma.
Plasma SHBG values obtained using the binding assay correlated well with immunoassay values in 179 subjects. The relationship between the two assays is similar for normal men, normal women, pregnant women, women with idiopathic hirsutism, women with PCOS, hyperprolactinaemic women, obese women and men presenting with wnaecomas~ia or interfertility. Cannell et al. previously reported that immunoassay and steroid-binding assay techniques yielded similar SHBG values in small numbers of normal men, normal women and hirsute women. Using the immunoassay we confirmed the abnormalities in plasma SHBG reported previously using the binding assay i.e. significantly lower mean SHBG levels in hirsute women, obese women, hyperprolactinaemic women and women with PCOS, than in normal women. 18-20 Irrespective of the method used there is a degree of overlap between plasma SHBG values in these groups of patients and those in normal women, as seen previously.I8-20 Physiological variations observed with the binding assay were also observed with the immunoassay i.e. higher levels in pregnant women than in normal women, and higher levels in normal women than in normal men."
Using the immunoassay we also confirmed our previous observation that the fall in plasma SHBG levels normally seen during the second decade of life occurs also in genetic males who fail to undergo puberty as in isolated gonadotropin deficiency and in two patients with complete androgen insensitivity." The elevation of plasma SHBG levels in men presenting with infertility or gynaecomastia seen in preliminary observations just reached significance at the 5% level using the binding assay, but failed to reach significance using the immunoassay. Examination of a greater number of subjects may resolve this matter. Plasma SHBG values in hirsute patients on anovulants measured by binding assay and immunoassay correlated very well. Irrespective of the method used, there were significant increases in plasma SHBG levels during treatment with Diane, Norinyl I and Microgynon 30, but not with Ovran 30. The highest SHBG levels were seen in patients treated with Diane. Plasma SHBG levels are increased by oestrogens and decreased by androgens. IS The differences in the effects of the four anovulants on SHBG levels may be attributed to differences in the oestrogen contents and in the 'androgenicity' of the progestagen component.P: 23 Oestrogens also bring about a reduction of ovarian steroid production by suppression of LH and FSH secretion mediated by effects on the hypothalamic-pituitary unit. The net result is a fall in circulating non-SHBG bound androgen levels. the desired therapeutic end-point in androgen excess states.
The plasma SHBG immunoassay has excellent precision. sensitivity and specificity and yields similar results to the binding assay. while being less technically demanding. The possibility has been raised10. II that physiological and pathological alterations in plasma SHBG levels could be due to changes in binding characteristics of SHBG rather than changes in concentration. In pregnant women the two methods compared in this study might be expected to yield similar results due to the calibration of the IRMA method. However. the close agreement between the binding capacity and immunoassay methods in all the conditions examined in this study indicates that the alterations in plasma SHBG levels observed in these conditions are due to changes in plasma SHBG concentrations rather than changes in the binding characteristics of SHBG.
